Purpose Extended-duration thromboprophylaxis (EDTPPX) is the practice of prescribing antithrombotic therapy for 21 days after discharge, commonly used in surgical patients who are at high risk for venothromboembolism (VTE). While guidelines recommend EDTPPX, criteria are vague due to a paucity of data. The criteria can be further informed by cost-effectiveness thresholds. This study sought to determine the VTE incidence threshold for the cost-effectiveness of EDTPPX compared to inpatient prophylaxis. Methods A decision tree was used to compare EDTPPX for 21 days after discharge to 7 days of inpatient prophylaxis with base case assumptions based on an abdominal oncologic resection without complications in an otherwise healthy individual. Willingness to pay was set at $50,000/quality-adjusted life year (QALY). Sensitivity analyses were performed to assess uncertainty within the model, with particular interest in the threshold for cost-effectiveness based on VTE incidence. Results EDTPPX was the dominant strategy when VTE probability exceeds 2.39 %. Given a willingness to pay threshold of $50, 000/QALY, EDTPPX was the preferred strategy when VTE incidence exceeded 1.22 and 0.88 % when using brand name or generic medication costs, respectively. Conclusions EDTPPX should be recommended whenever VTE incidence exceeds 2.39 %. When post-discharge estimated VTE risk is 0.88-2.39 %, patient preferences about self-injections and medication costs should be considered.
Introduction
Venothromboembolism (VTE) encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE) represents a major health care burden, leading the Surgeon General to release a call to action in 2008. Between 100,000 and 180, 000 deaths in the USA are attributable to VTE annually, and nearly four million surgical patients are at elevated risk each year.[ 1, 2 ] The Agency for Healthcare Research and Quality has stated that provision of thromboprophylaxis is one of the most important steps to improve patient safety. Many initiatives have focused on inpatient prophylaxis, yet increasing evidence demonstrates that VTE risk is prolonged well beyond the inpatient episode. The Million Women Study found that there was heightened VTE risk for up to 12 weeks following surgery, and nearly 40 % of all surgery-related VTE occur within 21 days after surgery. [ In an attempt to address this prolonged period of risk, randomized controlled trials in major abdominal oncologic resections have demonstrated that 28 days of low molecular weight heparin (LMWH) decreases the rate of both asymptomatic and symptomatic VTE compared to inpatient prophylaxis alone.
[ [5] [6] [7] These findings have led to national and international consensus guidelines recommending the use of extended-duration thromboprophylaxis (EDTPPX) following major abdominal or pelvic resections for cancer.[ 8, 9 ]. The use of LMWH for a total of 28 days following surgery is not a simple decision as there are trade-offs that require consideration. The cost of LMWH can be a considerable financial burden to both the patient and the health care system. [ 10 ] Recognition of this burden led the American College of Chest Physicians to include a comment about discussing EDTPPX with patients with particular attention to their financial preferences. [ 11 ] Another major trade-off for patients is the requirement for self-injections which is less preferred and has been associated with a decreased quality of life compared to oral agents. [ 
]
The trade-offs, particularly the increased cost associated with LMWH, necessitate an analysis of the economic feasibility of EDTPPX. Given LMWH's impact on quality of life, a cost-effectiveness analysis incorporating the patient perspective will help determine when EDTPPX should be applied.
This study is aimed at defining who would benefit from post-discharge thromboprophylaxis. To achieve this aim, this study utilizes a cost-effectiveness analysis to determine the threshold VTE incidence where extended-duration thromboprophylaxis following major oncologic abdominal resections is cost-effective.
Methods
A decision analytic model was developed to compare relative costs and health outcomes of two prophylactic strategies. The base case scenario was a major abdominal surgery for cancer in a middle-aged, otherwise healthy individual, with no history of prior VTE, who had a 7-day inpatient stay and successfully completed inpatient thromboprophylaxis and did not have any surgical complications. Two competing strategies were included in the model: inpatient prophylaxis for the 7-day inpatient stay only or an additional 21 days of low molecular weight heparin after discharge (28 days total).
The decision tree was developed using proprietary software (TreeAge Pro 2013 Software, Williamstown, MA, USA). The decision was modeled at post-operative day 7 where the patient either received 21 more days of low molecular weight heparin or received care as usual with no further thromboprophylaxis (Fig. 1) . Since LMWH is administered via a subcutaneous selfinjection that may be associated with poor patient compliance, patients were considered to be either compliant or noncompliant with EDTPPX. If non-compliant, the efficacy of EDTPPX was considered to drop to baseline and costs were considered to be the same as those prescribed the drug, assuming the drug had already been purchased. Compliant patients were considered to receive full benefit of prophylaxis. Bleeding risk and heparin-induced thrombocytopenia were not considered in the model since in randomized controlled trials of extended-duration thromboprophylaxis, neither was significantly increased in the EDTPPX cohort.[ 5, 6 ]. The model included development or no development of VTE. After VTE development, the event was categorized as either PE or DVT. If a PE occurred, the tree incorporated a risk of progression to death. If a DVT occurred, there was a possibility of progressing to post-thrombotic syndrome (PTS). There was no additional cost for death, while there was an additional cost associated with PTS. Due to relative infrequency, simultaneous PE and DVT were not considered and progression of DVT to PE was not included in the analysis.
Parameter estimations for the base case assumptions were based on best modeling practices. As event probability, utility, and cost were all based on symptomatic events, the estimated reduction in VTE after EDTPPX was based on the relative reduction in symptomatic events as well. Risk of VTE was considered constant across the additional 21 days of prophylaxis.
Cost
Cost was from the health care system perspective, and the cost following PE, VTE, and PTS was derived from PharMetrics Patient-Centric Database, comprised of fully adjudicated medical and pharmaceutical claims within the USA from 2004. Cost estimates were adjusted for inflation using the consumer price index for 2013 US health care dollars. LMWH became available as a generic drug in 2012, and analysis was performed using brand and subsequently generic drug prices. The inpatient regimen was considered to be the same, and thus, no difference in cost for the inpatient period was included. LMWH cost was modeled for 21 additional days of 40 mg LMWH using data from the outpatient pharmacy at the University of Rochester Medical Center in 2013 (Center OPUORM, personal . VTE-related costs were modeled over 1 year, and as such, no discount was included. The cost of VTE development in the intervention arm incurred the full medication cost as well as the additional cost associated with the event.
Health Outcomes
Effectiveness was defined from the patient perspective using quality-adjusted life years calculated using utility weights over a 1-year time horizon. No data on utility values following abdominal oncologic surgery were available; thus, utility values were extrapolated from other similar major surgeries.[ 16, 17 ].
Cost-Effectiveness Analysis
The preferred strategy thresholds were determined using the incremental cost-effectiveness ratio calculated using the difference in cost between the two interventions per unit difference in effect. The willingness to pay threshold was set at $50,000/ quality-adjusted life year (QALY). The threshold value of $50, 000/QALY is the common threshold for cost-effectiveness analysis in the USA.[ 18, 19 ].
Sensitivity Analysis
We used sensitivity analysis to evaluate the impact of uncertainty around baseline assumptions of the model. Ranges were based on the range of reported values and confidence intervals or were assigned wide ranges where evidence was not available.
Results
Cost was first evaluated independently with results stratified by brand versus generic medication costs. When brand name LMWH medication costs were used, EDTPPX minimized cost when the VTE probability reached 1.2 % (Fig. 2) . This threshold decreased to 0.2 % when using generic LMWH costs (Fig. 3 ). The effectiveness threshold was then evaluated independently using QALY as the unit of effectiveness. The use of brand or generic LMWH did not alter effectiveness results. EDTPPX became the preferred strategy when the VTE probability reached 2.4 % (Fig. 4) . Cost-effectiveness as determined by the incremental costeffectiveness ratio is reported stratified by brand vs. generic medication costs. When brand name LMWH costs were used, EDTPPX became the dominant strategy (both less costly and more effective) when VTE probability reached 2.39 %. Use of generic LMWH did not alter this threshold Table 2 .
When a competing intervention is not dominant, the preferential strategy depends on the willingness to pay which was set at 50,000/QALY. At this willingness to pay level, EDTPPX with brand medication costs was the preferred strategy when VTE probability reached 0.165 %. When generic medication costs were used, EDTPPX was preferred when VTE probability reached 0.88 %.
Inpatient prophylaxis was the dominant strategy (both less costly and more effective) if VTE probability was less than 1.22 and 0.165 % for brand and generic medication costs, respectively.
As shown in Fig. 5 , the model was most sensitive to the cost of medication. The next most important variable was the probability of VTE. The model was also sensitive to the cost of a DVT and PE, the disutility associated with LMWH use, the QALY associated with PE and DVT, the relative reduction in VTE after EDTPPX, and patient compliance. When evaluating the tornado diagram for the ICER, the model was most sensitive to the probability of VTE, the cost of medication, and the QALY associated with experiencing a DVT. While all other American College of Chest Physicians (ACCP) recommendations reference stratified risk scoring systems, the recommendation regarding EDTPPX does not, in large part because no such risk score yet exists. The ambiguity of high risk in the postdischarge setting may be another contributing factor to the lack of guideline compliance.
Instead of using the conceptual framework of "high risk" which at the outset is vague and referential, this study sought to define the appropriate use of EDTPPX as when it is costeffective. EDTPPX with generic LMWH is cost-effective when VTE probability exceeds 0.88 %, and when brand name LMWH medication costs were used, EDTPPX was costeffective when VTE probability exceeded 1.6 %. Within the National Surgical Quality Improvement Program database (2005-2009) after colon and rectal resections for cancer, the post-discharge symptomatic VTE rate at 30 days is 0.66 %.[ 14 ] Partial and total pancreatic resections for malignancy are associated with a post-discharge VTE incidence of 0.9 % at 90 days, and other major abdominal resections fall within this range. These incidence rates falls within the range where medication cost and patient rating of the utility of LMWH alter the cost-effectiveness of EDTPPX. Thus, for most major abdominal oncologic resections, a more nuanced approach to EDTPPX use is warranted.
This study also helps inform high risk for use in the ACCP guidelines. Regardless of whether medication was generic or Fig. 4 Effectiveness threshold for extended-duration thromboprophylaxis by probability of post-discharge VTE. Effectiveness threshold demonstrating that when probability of VTE exceeds 2.5 %, extended-duration thromboprophylaxis with LMWH is the preferred strategy to maximize effectiveness Given the importance of patient preferences within the cost-effectiveness model, patients within the 11-14 risk score range should have their decision individualized based on their opinions about the burden associated with selfinjections, availability of generic LMWH, and risk averseness to post-discharge VTE.
This study has limitations secondary to the level of uncertainty regarding the baseline estimates. This study was not meant to determine whether EDTPPX in abdominal oncologic resections is cost-effective at given baseline parameters, but rather determine the range of VTE for which it might be considered for use. Dominance of EDTPPX was stable to Fig. 5 Tornado diagram. c_medication cost of medication, p_VTE probability of VTE, c_DVT cost of DVT, u _LMWH utility of low molecular weight heparin, c-PE cost of pulmonary embolism, u_DVT utility of deep vein thrombosis, p _DVT probability of deep vein thrombosis, R_EDTPPX reduction in venothromboembolism with extended-duration thromboprophylaxis, u_PE utility of PE, p_compliance probability of compliance changes in medication costs within the sensitivity range, suggesting that the VTE risk estimate of 2.39 % for use is an appropriate estimate. There is limited data on utility weights following abdominal oncologic surgery, and thus, this data was extrapolated from existing literature for other major surgeries. It is possible that patients undergoing surgery for GI malignancies weigh both the surgery and subsequent complications such VTE differently. Changes in these utilities may alter ultimate results. The decision tree used in this analysis simplifies the relative complex disease course of venothromboembolism following surgery, but the model attempted to account for some of this uncertainty with a robust sensitivity analysis. This study focused only on the use of LMWH, while unfractionated heparin (UFH) is another choice consistent with guidelines. Future study may consider the use of UFH and thresholds for its use in EDTPPX.
Conclusion
Extended thromboprophylaxis with LMWH is the dominant cost-effective strategy when VTE incidence exceeded 2.39 % regardless of whether generic or brand name drug costs were assumed. When post-discharge VTE risk is estimated from 0.88 to 2.39 %, patient preferences about self-injections and medication costs should be considered to provide patients with an individualized decision that maximizes the costeffectiveness for them. These findings should be used to inform future guidelines about EDTPPX use following abdominal surgery for cancer. 
Discussion
Dr. Kimberly M. Brown (Galveston, TX): The authors have completed an interesting study of an important question relating to the use of extended thromboprophylaxis in GI cancer patients. It is clear that EDTPPX is more likely to benefit certain patients, and this paper illuminates a specific threshold of risk beyond which the most cost-effective strategy is to provide EDTPPX. 1. Given that the work of Bradley et al. demonstrated costeffectiveness of unfractionated heparin, please give a rationale as to why that strategy was not included in your analysis.
2. In the discussion, the authors criticize vague definitions of "high risk" and lack of a risk prediction model as contributing factors to poor compliance, but the results of their study depend on being able to calculate a patient's risk in order to determine cost-effectiveness (should one try to operationalize the conclusions of this paper). How would one determine the risk of a given patient in order to apply the proposed algorithm? 4. In the conclusions, the authors state that the findings of the paper should inform guidelines regarding colorectal surgery. Please comment as to if or how these findings should be applied to other abdominal surgery patients.
Closing Discussant
Dr. James Iannuzzi: Thank you for your comments and questions. The work of Bradley et al. was focused on evaluating a wide range of thromboprophylactic regimens including warfarin and aspirin that are not currently recommended for post-discharge thromboprophylaxis. While current ACCP guidelines do recommend either low weight molecular heparin or unfractionated heparin, the clinical trials leading to these guidelines focused on low molecular weight heparin only. Unfractionated heparin may remain a viable low-cost option; however, it is not a favored approach with a minority of colorectal surgeons using it for extended prophylaxis (unpublished data). We restricted our analysis to the most commonly used post-discharge thromboprophylactic agent with the purpose of determining when it is best utilized in congruence with the clinical trials that led to current guidelines.
Determining patient risk for individualized care is a growing trend in surgical care that likely increased medical efficiency. While previously no risk stratification is available for determining post-discharge VTE risk, we have recently developed just such a risk score aimed at the post-surgical discharge VTE risk prediction. The range of risk where extended-duration thromboprophylaxis is cost-effective includes the average VTE rates following major abdominal surgery, which bolsters current recommendations for its use in this population. However, individual patients may have lower risk and be spared extended-duration thromboprophylaxis, while others may clearly be at high risk making the decision easy. This paper demonstrates that intermediate-risk patients may benefit from extendedduration thromboprophylaxis, but including their preferences about shots and availability of generic drugs may be even more important and should be included in the decision making process.
In our paper, we considered both laparoscopic and open cases together in aggregate. Controversy continues to rage over whether there is a true difference in VTE based on operative approach. The studies utilized for baseline estimates of VTE rate were derived from NSQIP from 2005 to 2009; however, subsequent studies including 2010 data have corroborated these estimates.
While our initial conclusions were geared towards colorectal patients, our findings are generalizable to the wider cohort of major abdominal surgeries as the utility estimates and baseline parameters were derived from widely generalizable values. The risk scores that then inform an individualized patient approach also are non-specific and include all general surgery cases. We thus have now concluded that our findings can be applied to all major abdominal GI resections.
